Lilly's tirzepatide beats Novo's semaglutide in diabetes phase 3, but another study muddies picture

Lilly's tirzepatide beats Novo's semaglutide in diabetes phase 3, but another study muddies picture

Source: 
Fierce Biotech
snippet: 

Another phase 3 clinical trial of Eli Lilly’s tirzepatide in Type 2 diabetics has met its primary endpoint. The dual GIP/GLP-1 agonist beat Novo Nordisk’s semaglutide against multiple measures, although recent data on another dose of the rival drug suggest Lilly has a fight on its hands.